Jeffrey Chou (Joyce Chou)

Publication Activity (10 Years)

Years Active: 2020-2022
Publications (10 Years): 5

Top Topics

Randomized Controlled Trial

Extracorporeal Membrane Oxygenation

Acute Lymphoblastic Leukemia

Top Venues

Future oncology (London, England)

Clinical cancer research : an official journal of the American Association for Cancer Research

Targeted oncology

Molecular cancer therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Omid Hamid, Alberto A Chiappori, John A Thompson, Toshihiko Doi, Siwen Hu-Lieskovan, Ferry A L M Eskens, Willeke Ros, Adi Diab, Jean-Philippe Spano, Naiyer A Rizvi, Jeffrey S Wasser, Eric Angevin, Patrick A Ott, Alison Forgie, Wenjing Yang, Cen Guo, Jeffrey Chou, Anthony B El-Khoueiry
First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors. Journal for immunotherapy of cancer 10 (10) (2022)
Siwen Hu-Lieskovan, Fadi Braiteh, Juneko E Grilley Olson, Xiao Wang, Alison Forgie, Vinicius Bonato, Ira A Jacobs, Jeffrey Chou, Melissa Lynne Johnson
Association of Tumor Mutational Burden and Immune Gene Expression with Response to PD-1 Blockade by Sasanlimab Across Tumor Types and Routes of Administration. Targeted oncology 16 (6) (2021)
Adi Diab, Omid Hamid, John A Thompson, Willeke Ros, Ferry A L M Eskens, Toshihiko Doi, Siwen Hu-Lieskovan, Samuel J Klempner, Bishu Ganguly, Catherine Fleener, Xiao Wang, Tenshang Joh, Kai H Liao, Shahram Salek-Ardakani, Carrie Turich Taylor, Jeffrey Chou, Anthony B El-Khoueiry
A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients with Locally Advanced or Metastatic Cancers. Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Siwen Hu-Lieskovan, Gabriel G Malouf, Ira Jacobs, Jeffrey Chou, Li Liu, Melissa L Johnson
Addressing resistance to immune checkpoint inhibitor therapy: an urgent unmet need. Future oncology (London, England) 17 (11) (2021)
Amir A Al-Khami, Sawsan Youssef, Yasmina Abdiche, HoangKim Nguyen, Jeffrey Chou, Christopher R Kimberlin, Sherman M Chin, Cris Kamperschroer, Bart Jessen, Brent Kern, Natalija Budimir, Christopher P Dillon, Allison Xu, Jerry D Clark, Eugenia Kraynov, Arvind Rajpal, John C Lin, Shahram Salek-Ardakani
Pharmacologic Properties and Preclinical Activity of Sasanlimab, A High-affinity Engineered Anti-Human PD-1 Antibody. Molecular cancer therapeutics 19 (10) (2020)